Urology Times State of the Specialty Survey 2015

The conversation touched on risk stratification, which plays a central role in deciding among surgical options.

The approval is supported by landmark results from the pivotal phase 2 SANS-UUI trial.

Explore the latest insights on testosterone therapy, its benefits, and practical applications from leading urologists in men's health.

ArteraAI is a multimodal artificial intelligence biomarker test that can predict therapy benefit and prognosticate long-term outcomes in prostate cancer.

Pfizer has chosen to no longer pursue an expanded indication for talazoparib plus enzalutamide in non-HRR gene mutated mCRPC in the US as a result of this decision.